Question about future trials. With the number of Patients in the BETonMACE trial in CKD and cogintion arms with an average dosing length of 27 months, would a P II trial be necessary or would they be able to go directly to a P III trial for each of those indications? If the data from this trial is worth pursuing of course.

tada